Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint

Why is Trump doubling steel tariffs to 50%? How will OPEC+ oil output hike impact prices? Why is JPMorgan's Dimon warning about bond cracks? What triggered Tesla's recent stock volatility? How is AI threatening entry-level white collar jobs? Why are American consumers still pessimistic on economy? What caused leadership shake-up at ICE and deportations rise?

Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint

benzinga.com/news/health-care/25/05/45693375/summit-therapeutics-closely-watched-lung-cancer-study-of-ivonescimab-misses-overall-survival-end

Summit Therapeutics Inc. (NASDAQ:SMMT) released topline results on Friday from the Phase 3 HARMONi trial of ivonescimab plus platinum-doublet chemotherapy compared to placebo plus platinum-doublet chemotherapy for epidermal growth factor receptor (EGFR)-mutated, locally advanced or…

This story appeared on benzinga.com, 2025-05-30 13:01:33.